Celltrion Pharm Inc
KOSDAQ:068760
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
43 581.3789
65 400
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Celltrion Pharm Inc
Other Long-Term Assets
Celltrion Pharm Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Other Long-Term Assets
â‚©10.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
5%
|
|
|
Yuhan Corp
KRX:000100
|
Other Long-Term Assets
â‚©133.1B
|
CAGR 3-Years
56%
|
CAGR 5-Years
32%
|
CAGR 10-Years
31%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Other Long-Term Assets
â‚©217.4B
|
CAGR 3-Years
92%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Other Long-Term Assets
â‚©171.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Other Long-Term Assets
â‚©17.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
24%
|
CAGR 10-Years
25%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Other Long-Term Assets
â‚©10.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Celltrion Pharm Inc
Glance View
In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.
See Also
What is Celltrion Pharm Inc's Other Long-Term Assets?
Other Long-Term Assets
10.8B
KRW
Based on the financial report for Jun 30, 2025, Celltrion Pharm Inc's Other Long-Term Assets amounts to 10.8B KRW.
What is Celltrion Pharm Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
5%
Over the last year, the Other Long-Term Assets growth was -29%. The average annual Other Long-Term Assets growth rates for Celltrion Pharm Inc have been -14% over the past three years , -7% over the past five years , and 5% over the past ten years .